Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 1/20 | 0.48 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8038145 | 1.00 | GRIN1 (0.48) | GRIN1GRIN2AGRIN2BALDH1A1HSD17B10 | |
| SCHEMBL14312212 | 0.92 | SIGMAR1 (0.46) | GRIN1GRIN2AGRIN2BALDH1A1HSD17B10 | |
| SCHEMBL14312255 | 0.87 | CXCR4 (0.50) | GRIN1GRIN2AGRIN2BCHRM1OPRD1 | |
| SCHEMBL8654441 | 0.86 | CYP2D6 (0.54) | GRIN1GRIN2AGRIN2BHSD17B10P2RY6 | |
| SCHEMBL887952 | 0.84 | OPRD1 (0.47) | ALDH1A1OPRD1CYP3A4CYP2D6MAPT | |
| SCHEMBL22297856 | 0.84 | ALDH1A1 (0.49) | ALDH1A1CYP3A4CYP2D6MAPTMAPK1 | |
| SCHEMBL24728935 | 0.83 | HTT (0.49) | GRIN1GRIN2AGRIN2BALDH1A1LMNA | |
| SCHEMBL9707222 | 0.83 | GRIN1 (0.57) | GRIN1GRIN2AGRIN2BHSD17B10P2RY6 | |
| SCHEMBL14477643 | 0.83 | GRIN1 (0.37) | GRIN1GRIN2AGRIN2BALDH1A1HSD17B10 | |
| SCHEMBL17029293 | 0.82 | ALDH1A1 (0.50) | ALDH1A1CYP3A4CYP2D6MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4642489-A1 | CONJUGATE AND USES THEREOF | Full-Life Technologies HK Limited (HK) | 2025-11-05 | — | — | EP | claimed |
| WO-2025137443-A1 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING SOMATOSTATIN RECEPTORS AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| WO-2025137441-A1 | RADIOPHARMACEUTICALS TARGETING SOMATOSTATIN RECEPTOR 2 AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| WO-2024140670-A1 | CONJUGATE AND USES THEREOF | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2024-07-04 | — | — | WO | claimed |
| CN-113730606-B | CYP1B1 enzyme-targeted NIR/PET bimodal probe precursor and preparation and application thereof | 上海交通大学 | 2022-06-28 | — | — | CN | claimed |
| CN-106573959-B | Modified cyclic pentapeptides and uses thereof | 慕尼黑工业大学 | 2022-03-25 | — | — | CN | claimed |
| CN-122075404-A | Liquid formulations and methods for inhibiting pentetic acid degradation | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260124327-A1 | Compounds Targeting Carbonic Anhydrase IX and Uses Thereof | RAYZEBIO, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4724457-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Rayzebio, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4705299-A1 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING CARBONIC ANHYDRASE IX AND USES THEREOF | Rayzebio, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4642489-A1 | CONJUGATE AND USES THEREOF | Full-Life Technologies HK Limited (HK) | 2025-11-05 | — | — | EP | disclosed |
| WO-2024254339-A9 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| EP-4594337-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING EPHRIN TYPE-A RECEPTOR 2 AND USES THEREOF | Rayzebio, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| WO-2021255282-A1 | CONJUGATED AND LABELLED APELIN, PREPARATION AND USES THEREOF | UNIVERSITE D'AIX MARSEILLE (FR) | 2021-12-23 | — | — | WO | disclosed |
| EP-3152226-B1 | MODIFIED CYCLOPENTAPEPTIDES AND USES THEREOF | UNIV MUENCHEN TECH (DE) | 2019-05-29 | — | — | EP | disclosed |
| WO-2018154034-A1 | RADIOLABELED SOLUBLE CD146, PREPARATION AND USES THEREOF | UNIVERSITE D'AIX-MARSEILLE (FR) | 2018-08-30 | — | — | WO | disclosed |
| EP-3152226-A1 | MODIFIED CYCLOPENTAPEPTIDES AND USES THEREOF | Technische Universität München (DE) | 2017-04-12 | — | — | EP | disclosed |
| WO-2015185162-A1 | MODIFIED CYCLOPENTAPEPTIDES AND USES THEREOF | Technische Universität München (DE) | 2015-12-10 | — | — | WO | disclosed |
| US-9012604-B2 | Triazanonane derivatives or pharmaceutically acceptable salt thereof for enhanced fluorine-18 labeling | Snur & DB Foundation (KR) | 2015-04-21 | — | — | US | disclosed |
| US-9012604-B2 | Triazanonane derivatives or pharmaceutically acceptable salt thereof for enhanced fluorine-18 labeling | Snur & DB Foundation (KR) | 2015-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124327-A1 | Compounds Targeting Carbonic Anhydrase IX and Uses Thereof | CA9, CA13, CA4 | GRIN1 3833/4885GRIN2A 4240/4885GRIN2B 3623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.